DeHeng Advised GenFleet Therapeutics Inc.

on its Hundreds of Millions RMB Series B+ Financing

2021-01-29

GenFleet Therapeutics Inc. ("GenFleet") recently announced the completion of its hundreds of millions RMB Series B+ financing, invested by Northern Light Venture Capital (leading investor), HM Capital, Linden Asset, Shanjin Capital, and its shareholders CDH Investments as well as Panlin Capital. As GenFleet stepping into a new development stage of global multi-center clinical trials, the money raised will be used to speed up the development of its existing products and the conduct of its clinical trials, create an international cutting-edge R&D system, open the industrial layout in parallel, and continually complete the milestones of "global new" drug development.

DeHeng acted as the legal counsel for this project, and formed a project team with Zhang Lei, Fang Wen, and Shang Shuaili as the main members, representing Northern Light Venture Capital to participate in the legal due diligence, transaction documents drafting, project negotiation, and coordinate other investors and old shareholders to smoothly advance this project. The lawyers of the project team worked closely to complete the work of this project professionally and efficiently, and won the trust of customers and the company. Relying on years of accumulated rich project experience, industry resources, and rapid and in-depth professional research and services ability, the lawyers of project team are deeply engaged in professional legal services in new economic fields such as medicine, medical health, artificial intelligence, big data, TMT, cutting-edge manufacturing, etc., and will continue to provide high-level legal services to more clients.